OOIR: Observatory of International Research

Papers

(The TQCC of JAMA Oncology is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)

Article	Citations
Induction Chemotherapy for Advanced Nasopharyngeal Carcinoma—Is This the New Standard of Care?	1483
JAMA Oncology	602
Insights Into Immune-Mediated Disease and Cancer Risk—Delivering on the Promise of UK Biobank Big Data	534
Malignant Pericardial Effusion, or Fluid Around the Heart Due to Cancer	340
Analysis of Quality-of-Life Outcomes by Drug Class in Cancer Clinical Trials—Reply	309
Error in Text	274
Errors in Key Points and Abstract	269
Stargazers	253
Radiation-Associated Secondary Cancer in Patients With Breast Cancer Harboring TP53 Germline Variants	243
Biomarker Analysis of Vistusertib Plus Paclitaxel Regimen	243
Active Cellular Immunotherapy in the Desert of Advanced Prostate Cancer	242
Sexual Rehabilitation Needs of Gay and Bisexual Men With Cancer	242
Overall Survival in the CAIRO5 Clinical Trial	235
Limitations in Quantitative Harm-Benefit Assessment in Immuno-Oncology	219
Piercing the Fog	197
Nationwide Response to Carboplatin and Cisplatin Shortages in Lung Cancer	189
Transplant-Free Approach in Relapsed Hodgkin Lymphoma in Children, Adolescents, and Young Adults	186
The Implications of the Supreme Court Decision to Overturn Roe v Wade for Women With Pregnancy-Associated Cancers	180
Methodology Concerns Regarding Claims Data Studies in Transgender Health—Reply	179
The Multidisciplinary Cancer Conference	167
Immunotherapy in Prepatients—Preventing or Promoting a Malignant Transformation?	151
Firearm Safety for Patients Diagnosed With Cancer—A Role in Suicide Prevention	148
Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia	146
Unrelated Donor Age and Recipient Outcomes After Posttransplant Cyclophosphamide vs Conventional Prophylaxis	144
Systemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors	136

Ribociclib Plus Endocrine Therapy in Hormone Receptor–Positive/ ERBB2 -Negative Early Breast Cancer	133
Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration	133
Human Leukocyte Antigen Class I Antigen-Processing Machinery Upregulation by Anticancer Therapies in the Era of Checkpoint Inhibitors	130
Concerns Regarding the Utility of High-Risk Pancreatic Cancer Surveillance—Reply	129
Association Between Overall Survival and the Tendency for Cancer Programs to Administer Neoadjuvant Chemotherapy for Patients With Advanced Ovarian Cancer	129
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung Cancer	127
Long-term Effect of Machine Learning–Triggered Behavioral Nudges on Serious Illness Conversations and End-of-Life Outcomes Among Patients With Cancer	127
Established Cancer Predisposition Genes in Single and Multiple Cancer Diagnoses	124
The Global Economic Cost of Cancer—Estimating It Is Just the First Step!	124
Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab	119
Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab	118
Diversity Trends by Sex and Underrepresented in Medicine Status Among US Radiation and Medical Oncology Faculty Over 5 Decades	114
Internal Mammary Nodal Irradiation Debate for Node-Positive Breast Cancer—Has the Needle Moved?—Reply	112
SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients With Cancer in the US	110
Association of 5α-Reductase Inhibitor Use With Prostate Cancer–Specific Mortality—Reply	110
Use of Participation to Prevalence Ratio for Evaluating the Representation Status of Women in Oncology Clinical Trials—Reply	108
The SOUND Randomized Clinical Trial Results	106
Variability in COVID-19 Vaccine Response Among People With Cancer	104
Results of the TARGET-TP Randomized Clinical Trial	104
Is Appendiceal Cancer a Lynch Syndrome–Associated Cancer?	103
Immunotherapy Before Chemoradiotherapy—More Is Better?	101
An Atypical Rash on the Chest	101
Unplanned Hospitalization Prediction During Chemoradiotherapy Via Machine Learning Classifiers—Reply	99
Trauma	96
Shifting Toward Precision Oncology in SCLC Treatment	96
JAMA Oncology	94
Alteration of the Tumor Microenvironment With Intratumoral Dendritic Cells Before Chemotherapy in ERBB2 Breast Cancer	93
The Most Difficult Lesson From Cancer Just Might Be Its Most Valuable	90
Association Between Age and Survival Trends in Advanced Non–Small Cell Lung Cancer After Adoption of Immunotherapy	89
Coding Errors in Study of Eligibility for Lung Cancer Screening	89
Error in Text	88
Disparities in Trends of Gastroenteropancreatic Neuroendocrine Tumor Incidence	87
Caution Regarding Assessment of Toxic Effects and Survival in Treatment De-escalation With Radiotherapy vs Transoral Surgery for Human Papillomavirus–Associated Oropharyngeal Cancer	85
Steroid Dose and Duration, Immortal Time Bias, and Survival After High-grade Immune-Related Adverse Events—Reply	85
JAMA Oncology	84
Clinical Trial Diversity—Will We Know It When We See It?	83
Effect of Supine vs Prone Breast Radiotherapy on Acute Toxic Effects of the Skin Among Women With Large Breast Size	82
National Trends in Dexrazoxane and Cardiovascular Health Care Utilization for Children With Acute Myeloid Leukemia	81
Unwinding of Medicaid Continuous Enrollment Exposes Millions to Disrupted Care—“Be Kind, Rewind”	81
Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers	79
Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer	78
Natural Language Processing–Assessed Unmet Medical and Social Needs in Cancer Crowdfunding Stories	78
Accelerated Approval Is Not Conditional Approval	78
Project Optimus: Is the US Food and Drug Administration Waiving Dose Optimization for Orphan Drugs?	77
Undiagnosed Cancer Cases in the US During the First 10 Months of the COVID-19 Pandemic	77
Magnetic Resonance Imaging or Confirmatory Biopsy for Patients With Prostate Cancer Receiving Active Surveillance	76
Proton Craniospinal Irradiation for Patients With Leptomeningeal Metastasis	75
Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer	75
Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms	75
Effects of Gonadotropin-Releasing Hormone Analogs on Ovarian Function Against Chemotherapy-Induced Gonadotoxic Effects in Premenopausal Women With Breast Cancer in China	74

Assessment of Racial Disparity in Survival Outcomes for Early Hormone Receptor–Positive Breast Cancer After Adjusting for Insurance Status and Neighborhood Deprivation	74
Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma	74
Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set	73
Second Primary Cancer After Chimeric Antigen Receptor–T-Cell Therapy	73
Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer	73
Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Don	73
Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia	73
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent	72
Prostate-Specific Membrane Antigen PET-Guided Intensification of Salvage Radiotherapy After Radical Prostatectomy	71
BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients	69
Rethinking End Points in Modern Oncology Trials—Beyond the P Value	69
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma	69
Trends in the Characteristics, Treatment, and Outcomes of Rectal Adenocarcinoma in the US From 2004 to 2019	69
On Accelerated Aging—A Phenomenon in Survivors of Childhood Cancer	66
Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy Using a Novel Imaging Analysis	66
Is the Delphi’s Oracle Pertinent to Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma?—Reply	65
Change of Article Status to Open Access	65
JAMA Oncology	64
Does Circulating Tumor DNA Measure Up to Prostate-Specific Antigen?	64
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer—The A021501 Trial—Reply	63
Methodological Issues in Study of Daily Insulin Dose and Cancer Risk Among Patients With Type 1 Diabetes	63
Exposure Histories and Cancer Risk—What Can We Learn?	62
JAMA Oncology Peer Reviewers in 2021	62
Challenges in Shared Care Research in Hematopoietic Cell Transplantation—Reply	61
Standardized Definitions for Efficacy End Points for Adjuvant Trials—The Updated STEEP Criteria	61
Analysis of Association of Radiation Therapy With Risk of Adverse Events in Patients Receiving Immunotherapy Using Pooled Trial Data Matched by Propensity Score	61
Role of Patient-Reported Outcome Measures in the Inpatient Setting—Reply	61
Caution Regarding Assessment of Toxic Effects and Survival in Treatment De-escalation With Radiotherapy vs Transoral Surgery for Human Papillomavirus–Associated Oropharyngeal Cancer	60
Searching Beyond Programmed Cell Death Ligand 1 in Metastatic Breast Cancer—Still Haven’t Found What We’re Looking For	60
JAMA Oncology	60
Activity of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma	59
Rates of and Factors Associated With Patient Withdrawal of Consent in Cancer Clinical Trials	58
Artificial Intelligence–Detected Tumor-Infiltrating Lymphocytes and Outcomes in Anti–PD-1–Based Treated Melanoma	58
Consistent Adherence to Physical Activity Guidelines and Digestive System Cancer Risk and Mortality	57
Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor–Positive Breast Cancer	57
“You’ve Got Mail”—Receiving Bad News Through a Patient Portal	57
The Children’s Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers	56
Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer	56
Treatment of Adults With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia—From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens	56
Association of Genetic Ancestry With the Molecular Subtypes and Prognosis of Childhood Acute Lymphoblastic Leukemia	55
Self-reported Transportation Barriers to Health Care Among US Cancer Survivors	55
Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma	54
Global Stage Distribution of Breast Cancer at Diagnosis	54
Effect of Elective Internal Mammary Node Irradiation on Disease-Free Survival in Women With Node-Positive Breast Cancer	54
Dose-Adjusted EPOCH Plus Inotuzumab Ozogamicin in Adults With Relapsed or Refractory B-Cell ALL	54
Endocrine Society Hypercalcemia of Malignancy Guidelines	53
The ORATOR Trials Have Spoken—Where Do We Go From Here?	53
Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non−Small Cell Lung Cancer	53
Characterizing Lung Cancer in Li-Fraumeni Syndrome	53
Sunsets	52
Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer	52
Should DDGP Regimen Be the Standard of Care for Advanced Extranodal NK/T-Cell Lymphoma? The New Staging System Matters	52
Duration and Dose of Adjuvant Zoledronic Acid for Treatment of Early Breast Cancer—Reply	52
JAMA Oncology	52
Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer	52
Overall Survival With Adjuvant mFOLFIRINOX for Pancreatic Cancer	51
Oral Mucosal Pigmentation in a Patient With Mycosis Fungoides	51
Immunotherapy Benefit Over Best Supportive Care in Hepatocellular Cancer With Child-Pugh B Dysfunction—Reply	51
JAMA Oncology	51
Valid Analysis of Brain-Specific Progression-Free Survival	51
The Oncology Industrial Complex—Community Oncology Must Be Given a Seat at the Table—Reply	49
Exploration of Clinician Perspectives on Multidisciplinary Tumor Board Function Beyond Clinical Decision-making	49
Errors in Figures 2 and 3	49
Reshuffle	48
COVID-19 and Cancer	48
MGMT Promoter Methylation and Chemotherapy Outcomes in Low-Grade and Anaplastic Gliomas	48
Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer	47
Recurrence of Non–Small Cell Lung Cancer With Visceral Pleural Invasion	47
Managing Cancer Pain in Patients With Opioid Use Disorder or Nonmedical Opioid Use	47
Effect of Capecitabine Maintenance Therapy Plus Best Supportive Care vs Best Supportive Care Alone on Progression-Free Survival Among Patients With Newly Diagnosed Metastatic Nasopharyngeal Carcinoma	47
Radiotherapy With a 12-Gene Expression Assay for Ductal Carcinoma In Situ	46
Immune Checkpoint Inhibitor Therapy Before Nephrectomy for Locally Advanced and Metastatic Renal Cell Carcinoma	46
Relentless	46
Effect of a Symptom Monitoring Intervention for Patients Hospitalized With Advanced Cancer	45
Antiandrogen Treatment vs Active Surveillance for Patients With Prostate Cancer—Reply	45
Association of Patient-Reported Outcomes With Subsequent Nonfatal Self-injury After a New Cancer Diagnosis	45
Genetic Testing in Men With Metastatic Castration-Resistant Prostate Cancer	45
Artificial Intelligence—From Starting Pilots to Scalable Privilege	45
Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer	45
Personalized Radiation Therapy—Spurning the “One Size Fits All” Approach	45

Management of Down Syndrome–Associated Leukemias	44
Shared Local Oncology Care After Allogeneic Hematopoietic Cell Transplantation	43
Public Awareness of the Association Between Alcohol and Cancer in the US	43
Comparing Risk for Second Primary Cancers After Intensity-Modulated vs 3-Dimensional Conformal Radiation Therapy for Prostate Cancer, 2002-2015	43
Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer	43
Assessment of Phase 3 Randomized Clinical Trials Including Patients With Leptomeningeal Disease	43
Effectiveness of Aerobic Exercise and Tai Chi Interventions on Sleep Quality in Patients With Advanced Lung Cancer	43
Integrating Community Health Workers Into Care for Patients With Advanced Stages of Cancer—Fragility Index Analysis	42
The SOUND Randomized Clinical Trial Results—Reply	42
Dog Aloisanov Helped Diagnose My Cancer	42
Antiandrogen Treatment vs Active Surveillance for Patients With Prostate Cancer	42
Smoking Status of the US Cancer Population and a New Perspective From the National Cancer Database	42
Change of Article Status to Open Access	42
JAMA Oncology	42
Scattered Painful Papulonodules in an Older Woman	42
Advancing Truth in Oncology by Complementing Clinical Trials With Evidence From Clinical Practice	42
Genetic Ancestry–Based Differences in Biomarker-Based Eligibility for Precision Oncology Therapies	41
Two Hands, One Journey	41
Error in Figure 1	41
Stereotactic Radiosurgery vs Conventional Radiotherapy for Spine Metastases	41
Errors in Figure 3	41
Locally Advanced Relapse May Not Be Equal to Stage 3 Non–Small Cell Lung Cancer	40
Error in Figure	40
Immunotherapy Benefit Over Best Supportive Care in Hepatocellular Cancer With Child-Pugh B Dysfunction	39
Somebody Else’s Palms	39
An Algorithm as a Biomarker for Response to Immune Checkpoint Inhibitor Therapy	39
The Case for Allowing Proton Beam Therapy on Head and Neck Cooperative Group Studies	39
Financial Toxicity Among Asian American Cancer Survivors	38
Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer	38
Carboplatin During Craniospinal Radiotherapy for Children With Group 3 Medulloblastoma—A New Standard of Care?—Reply	38
Error in Figure 1	38
Cervical Cancer Incidence in the US-Affiliated Pacific Islands	38
Risk Factors for Valvulopathy Among Childhood Cancer Survivors	38
Unintended Consequences of Patient Portal Access	38
Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients	38
PARP Inhibitors for Breast Cancer Treatment	37
Is Regional Nodal Radiotherapy Necessary for Patients With cN1 and ypN0 Breast Cancer After Neoadjuvant Chemotherapy?—Reply	37
Association of Adjuvant Chemotherapy in Patients With Resected Pancreatic Adenocarcinoma After Multiagent Neoadjuvant Chemotherapy	37
Increasing the Uptake of Cancer Risk Management Strategies for Women With BRCA1/2 Sequence Variations	37
Integrating Oncology Lessons Across Tumor Types From Kidney to Prostate—A Good-Risk Shift	37
Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor–Positive/ERBB2-Positive Early Breast Cancer	37
Use of Single-Arm Trials for US Food and Drug Administration Drug Approval in Oncology, 2002-2021	37
Postoperative Restrictive Opioid Protocols and Durable Changes in Opioid Prescribing and Chronic Opioid Use	37
Dual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid Carcinoma	37
Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer	37
Net Clinical Benefit as Measure of Treatment Benefit Among Older Adults With Advanced Incurable Non–Small Cell Lung Cancer—Reply	36
Is 2045 Optimistic?—Concerns Regarding Rising Vaccine Hesitancy—Reply	36
Change to Open Access Status	36
An Intramedullary Enigma	36
JAMA Oncology	36
Proton FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases	36
Error in Author Surname	36
A Case of Multiple Hemorrhagic Friable Nodules	36
Government Funding for the Development of Enzalutamide	35
Error in the Additional Contributions Section	35
Comment on Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer	35
Change to Open Access	35
Assessing Response for Nivolumab Plus Ipilimumab in Squamous Cell Carcinoma of the Head and Neck—Reply	35
Duration and Dose of Adjuvant Zoledronic Acid for Treatment of Early Breast Cancer	35
Racial Disparities and Survival Outcomes in Breast Cancer—Reply	35
Patient Harassment of Medical Trainees	34
Childhood Cancer Survivor Risk Estimates and Age, Overdispersion, and Social Context—Reply	34
Implementing Smoking Cessation Interventions for Tobacco Users Within Oncology Settings	34
Reexamining Social Determinants of Health Data Collection in the COVID-19 Era	34
Osimertinib in Patients With Non–Small Cell Lung Cancer and Uncommon EGFR Mutations—Chasing Unicorns?	34
Overall Survival in the CAIRO5 Clinical Trial	34
Charting the Path to Systemic Therapy De-escalation—Oligometastatic Kidney Cancer as a Paradigm	34
Differences in Cancer Phenotypes Among Frequent CHEK2 Variants and Implications for Clinical Care—Checking CHEK2	33
SARS-CoV-2 Antibody Response to 2 or 3 Doses of the BNT162b2 Vaccine in Patients Treated With Anticancer Agents	33
A Paradigm Shift Toward Population-Based MRI-Targeted Prostate Cancer Screening	33
Long-Term Toxicity of Immune Checkpoint Inhibitors—Time to Widen the Lens	33
Implementing Resource-Stratified Guidelines in LMICs—More Issues Than Solutions	33
Immunotherapy Strategies After Immune Checkpoint Inhibitor Exposure in Renal Cell Carcinoma	33
The Urgent Need for Affordability Curricula at US Medical Schools	33
Assessment of Toxic Effects and Survival in Treatment Deescalation With Radiotherapy vs Transoral Surgery for HPV-Associated Oropharyngeal Squamous Cell Carcinoma	32
Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer	32
Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue	32
Association of Second-generation Antiandrogens With Cognitive and Functional Toxic Effects in Randomized Clinical Trials	32
Blood Clots, or Thrombosis, in Patients With Cancer	31
Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor–Positive, ERBB2-Negative Breast Cancer	31
Tepotinib Treatment in Patients With MET Exon 14–Skipping Non–Small Cell Lung Cancer	31
Watch and Wait for Near-Complete Responders—A Word of Caution	30
Atezolizumab and Trastuzumab Plus Chemotherapy for ERBB2-Positive Locally Advanced Resectable Gastric Cancer	30
Aiming for the Cure in ERBB2-Positive Metastatic Breast Cancer—Should We Go “All In”?	30
JAMA Oncology—The Year in Review, 2023	30
USPSTF Lung Cancer Screening Guidelines and Disparities in Screening Adherence	30
Lazertinib in EGFR-Variant Non–Small Cell Lung Cancer With CNS Failure to Prior EGFR Tyrosine Kinase Inhibitors	30
Results of the TARGET-TP Randomized Clinical Trial—Reply	30
Nontumor Cells in Tumor Samples Bias Expression-Based Models	30
High-Dose Aumolertinib for Untreated EGFR-Variant Non–Small Cell Lung Cancer With Brain Metastases	30
Errors in Byline	30
FOLFOX/FOLFIRI–Bevacizumab for Unresectable Colorectal Liver Metastases	29
Is Pertuzumab Plus Trastuzumab Without Chemotherapy a Reasonable Treatment for ERBB2-Positive Metastatic Breast Cancer?—Reply	29
Concerns Regarding the Utility of High-Risk Pancreatic Cancer Surveillance	29
Integrating Community Health Workers Into Care for Patients With Advanced Stages of Cancer—Fragility Index Analysis—Reply	29